347 related articles for article (PubMed ID: 25834145)
1. Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance.
Duluc C; Moatassim-Billah S; Chalabi-Dchar M; Perraud A; Samain R; Breibach F; Gayral M; Cordelier P; Delisle MB; Bousquet-Dubouch MP; Tomasini R; Schmid H; Mathonnet M; Pyronnet S; Martineau Y; Bousquet C
EMBO Mol Med; 2015 Jun; 7(6):735-53. PubMed ID: 25834145
[TBL] [Abstract][Full Text] [Related]
2. Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts.
Moatassim-Billah S; Duluc C; Samain R; Jean C; Perraud A; Decaup E; Cassant-Sourdy S; Bakri Y; Selves J; Schmid H; Martineau Y; Mathonnet M; Pyronnet S; Bousquet C
Oncotarget; 2016 Jul; 7(27):41584-41598. PubMed ID: 27177087
[TBL] [Abstract][Full Text] [Related]
3. Implication of 4E-BP1 protein dephosphorylation and accumulation in pancreatic cancer cell death induced by combined gemcitabine and TRAIL.
Elia A; Henry-Grant R; Adiseshiah C; Marboeuf C; Buckley RJ; Clemens MJ; Mudan S; Pyronnet S
Cell Death Dis; 2017 Dec; 8(12):3204. PubMed ID: 29233971
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages.
Samain R; Brunel A; Douché T; Fanjul M; Cassant-Sourdy S; Rochotte J; Cros J; Neuzillet C; Raffenne J; Duluc C; Perraud A; Nigri J; Gigoux V; Bieche I; Ponzo M; Carpentier G; Cascone I; Tomasini R; Schmid HA; Mathonnet M; Nicolle R; Bousquet MP; Martineau Y; Pyronnet S; Jean C; Bousquet C
Cell Mol Gastroenterol Hepatol; 2021; 11(5):1405-1436. PubMed ID: 33482394
[TBL] [Abstract][Full Text] [Related]
5. eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer.
Müller D; Shin S; Goullet de Rugy T; Samain R; Baer R; Strehaiano M; Masvidal-Sanz L; Guillermet-Guibert J; Jean C; Tsukumo Y; Sonenberg N; Marion F; Guilbaud N; Hoffmann JS; Larsson O; Bousquet C; Pyronnet S; Martineau Y
JCI Insight; 2019 Nov; 4(21):. PubMed ID: 31672935
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
Awasthi N; Yen PL; Schwarz MA; Schwarz RE
J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
[TBL] [Abstract][Full Text] [Related]
7. Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC.
Alhothali M; Mathew M; Iyer G; Lawrence HR; Yang S; Chellappan S; Padmanabhan J
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31100813
[TBL] [Abstract][Full Text] [Related]
8. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer.
Ito D; Fujimoto K; Mori T; Kami K; Koizumi M; Toyoda E; Kawaguchi Y; Doi R
Int J Cancer; 2006 May; 118(9):2337-43. PubMed ID: 16331623
[TBL] [Abstract][Full Text] [Related]
9. Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer.
Neumann CCM; von Hörschelmann E; Reutzel-Selke A; Seidel E; Sauer IM; Pratschke J; Bahra M; Schmuck RB
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):461-472. PubMed ID: 30243879
[TBL] [Abstract][Full Text] [Related]
10. Twist1-mediated 4E-BP1 regulation through mTOR in non-small cell lung cancer.
Lv T; Wang Q; Cromie M; Liu H; Tang S; Song Y; Gao W
Oncotarget; 2015 Oct; 6(32):33006-18. PubMed ID: 26360779
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
[TBL] [Abstract][Full Text] [Related]
12. Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1.
Wang J; Ye Q; Cao Y; Guo Y; Huang X; Mi W; Liu S; Wang C; Yang HS; Zhou BP; Evers BM; She QB
Nat Commun; 2017 Dec; 8(1):2207. PubMed ID: 29263324
[TBL] [Abstract][Full Text] [Related]
13. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.
Yellen P; Saqcena M; Salloum D; Feng J; Preda A; Xu L; Rodrik-Outmezguine V; Foster DA
Cell Cycle; 2011 Nov; 10(22):3948-56. PubMed ID: 22071574
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance.
D'Errico G; Alonso-Nocelo M; Vallespinos M; Hermann PC; Alcalá S; García CP; Martin-Hijano L; Valle S; Earl J; Cassiano C; Lombardia L; Feliu J; Monti MC; Seufferlein T; García-Bermejo L; Martinelli P; Carrato A; Sainz B
Oncogene; 2019 Jul; 38(27):5469-5485. PubMed ID: 30936462
[TBL] [Abstract][Full Text] [Related]
15. PI3K-Akt-mTOR axis sustains rotavirus infection via the 4E-BP1 mediated autophagy pathway and represents an antiviral target.
Yin Y; Dang W; Zhou X; Xu L; Wang W; Cao W; Chen S; Su J; Cai X; Xiao S; Peppelenbosch MP; Pan Q
Virulence; 2018 Jan; 9(1):83-98. PubMed ID: 28475412
[TBL] [Abstract][Full Text] [Related]
16. Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.
Massihnia D; Avan A; Funel N; Maftouh M; van Krieken A; Granchi C; Raktoe R; Boggi U; Aicher B; Minutolo F; Russo A; Leon LG; Peters GJ; Giovannetti E
J Hematol Oncol; 2017 Jan; 10(1):9. PubMed ID: 28061880
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
Adesso L; Calabretta S; Barbagallo F; Capurso G; Pilozzi E; Geremia R; Delle Fave G; Sette C
Oncogene; 2013 Jun; 32(23):2848-57. PubMed ID: 22797067
[TBL] [Abstract][Full Text] [Related]
18. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Qiu J; You L; Zheng L; Zhang T; Zhao Y
J Exp Clin Cancer Res; 2018 Nov; 37(1):274. PubMed ID: 30419950
[TBL] [Abstract][Full Text] [Related]
19. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
Zhang L; Yao J; Li W; Zhang C
Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
[TBL] [Abstract][Full Text] [Related]
20. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis.
Hu LP; Zhang XX; Jiang SH; Tao LY; Li Q; Zhu LL; Yang MW; Huo YM; Jiang YS; Tian GA; Cao XY; Zhang YL; Yang Q; Yang XM; Wang YH; Li J; Xiao GG; Sun YW; Zhang ZG
Clin Cancer Res; 2019 Feb; 25(4):1318-1330. PubMed ID: 30420446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
